This Medudy course is a video tutorial for physicians on the topic of "Tivozanib plus nivolumab vs. tivozanib mono in renal cell carcinoma". The format used here is a so-called "Journal Club Summary", in which we summarize the latest and most clinically relevant studies for you.
Immune checkpoint inhibitors and tyrosine kinase inhibitors of vascular endothelial growth factor are cornerstones of first-line treatment of advanced renal cell carcinoma.
However, the optimal treatment sequence after progression is unknown.
This study was specifically designed to evaluate the clinical outcomes of tivozanib plus nivolumab compared to tivozanib monotherapy in patients with metastatic renal cell carcinoma.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
At the end of this course you will know
- the clinical background and relevance of the research question under investigation
- the study design and methodology of the publication to answer the research question
- the results and key takeaways of the publication
- the conclusion of the publication and possible limitations
